Acute erythroid leukemia with <20% bone marrow blasts is clinically and biologically similar to myelodysplastic syndrome with excess blasts

In acute erythroleukemia, erythroid/myeloid subtype, blasts usually comprise 5–19% of total bone marrow cells, similar to the myelodysplastic syndrome subtype refractory anemia with excess blasts; recent studies have raised the question if acute erythroleukemia should be considered as a myelodysplas...

Full description

Saved in:
Bibliographic Details
Published in:Modern pathology 2016-10, Vol.29 (10), p.1221-1231
Main Authors: Wang, Sa A, Patel, Keyur P, Pozdnyakova, Olga, Peng, Jie, Zuo, Zhuang, Cin, Paola Dal, Steensma, David P, Hasserjian, Robert P
Format: Article
Language:English
Subjects:
692/499
692/699/67/1990
Adolescent
Adult
Aged
Aged, 80 and over
Anemia
Bone marrow
Chemotherapy
Classification
Female
Hospitals
Humans
Laboratory Medicine
Leukemia
Leukemia, Erythroblastic, Acute - classification
Leukemia, Erythroblastic, Acute - pathology
Male
Medical prognosis
Medicine
Medicine & Public Health
Middle Aged
Myelodysplastic syndromes
Myelodysplastic Syndromes - pathology
original-article
Pathology
Retrospective Studies
Tumors
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In acute erythroleukemia, erythroid/myeloid subtype, blasts usually comprise 5–19% of total bone marrow cells, similar to the myelodysplastic syndrome subtype refractory anemia with excess blasts; recent studies have raised the question if acute erythroleukemia should be considered as a myelodysplastic syndrome subtype. We reviewed 77 de novo acute erythroleukemia and 279 de novo refractory anemia with excess blasts from three large medical centers. Compared to refractory anemia with excess blasts, acute erythroleukemia patients had higher total bone marrow blasts, lower platelets, hemoglobin, and absolute neutrophil counts, with more patients being assigned a very-poor-karyotype risk and very-high Revised International Prognostic Scoring System score. Induction chemotherapy was administered to 55% of acute erythroleukemia patients, but was not associated with longer overall survival compared to acute erythroleukemia patients treated with lower-intensity therapies or supportive care (P=0.44). In multivariable analysis of all patients, Revised International Prognostic Scoring System very high (P
ISSN:0893-3952
1530-0285
DOI:10.1038/modpathol.2016.118